Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/74221
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Almeida, Andreia | por |
dc.contributor.author | Fernandes, Eduarda | por |
dc.contributor.author | Sarmento, Bruno | por |
dc.contributor.author | Lúcio, M. | por |
dc.date.accessioned | 2021-10-04T11:42:06Z | - |
dc.date.available | 2021-10-04T11:42:06Z | - |
dc.date.issued | 2021-06-12 | - |
dc.identifier.citation | Almeida, A.; Fernandes, E.; Sarmento, B.; Lúcio, M. A Biophysical Insight of Camptothecin Biodistribution: Towards a Molecular Understanding of Its Pharmacokinetic Issues. Pharmaceutics 2021, 13, 869. https://doi.org/10.3390/pharmaceutics13060869 | por |
dc.identifier.uri | https://hdl.handle.net/1822/74221 | - |
dc.description.abstract | Camptothecin (CPT) is a potent anticancer drug, and its putative oral administration is envisioned although difficult due to physiological barriers that must be overcome. A comprehensive biophysical analysis of CPT interaction with biointerface models can be used to predict some pharmacokinetic issues after oral administration of this or other drugs. To that end, different models were used to mimic the phospholipid composition of normal, cancer, and blood–brain barrier endothelial cell membranes. The logD values obtained indicate that the drug is well distributed across membranes. CPT-membrane interaction studies also confirm the drug’s location at the membrane cooperative and interfacial regions. The drug can also permeate membranes at more ordered phases by altering phospholipid packing. The similar logD values obtained in membrane models mimicking cancer or normal cells imply that CPT has limited selectivity to its target. Furthermore, CPT binds strongly to serum albumin, leaving only 8.05% of free drug available to be distributed to the tissues. The strong interaction with plasma proteins, allied to the large distribution (VD<sub>SS</sub> = 5.75 ± 0.932 L·Kg<sup>−1</sup>) and tendency to bioaccumulate in off-target tissues, were predicted to be pharmacokinetic issues of CPT, implying the need to develop drug delivery systems to improve its biodistribution. | por |
dc.description.sponsorship | This work was supported by Fundação para a Ciência e Tecnologia (FCT) in the framework of the Strategic Funding [UID/FIS/04650/2019], and by the project CONCERT [POCI-01- 0145-FEDER-032651 and PTDC/NAN-MAT/326512017], co-financed by the European Regional Development Fund (ERDF), through COMPETE 2020, under Portugal 2020, and FCT I.P. The authors thank Elettra Sincrotone and Sigrid Bernstorff, Trieste, Italy, for beam time and support through the project 20155321. Marlene Lúcio thanks FCT and ERDF for doctoral position [CTTI-150/18-CF (1)] in the ambit of the project CONCERT. Andreia Almeida (SFRH/BD/118721/2016) and Eduarda Fernandes (SFRH/BD/147938/2019) grants are supported by FCT, POPH and FEDER/COMPETE. | por |
dc.language.iso | eng | por |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | por |
dc.relation | UID/FIS/04650/2019 | por |
dc.relation | POCI-01- 0145-FEDER-032651 | por |
dc.relation | PTDC/NAN-MAT/326512017 | por |
dc.relation | SFRH/BD/118721/2016 | por |
dc.relation | SFRH/BD/147938/2019 | por |
dc.rights | openAccess | por |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | por |
dc.subject | Camptothecin | por |
dc.subject | Drug distribution | por |
dc.subject | Drug-membrane interaction | por |
dc.subject | Biophysical profiling | por |
dc.subject | Biomimetic models | por |
dc.subject | Partition coefficient | por |
dc.subject | ADMET/PK prediction | por |
dc.subject | Small and wide-angle X-ray diffraction | por |
dc.subject | Fluorescence spectroscopy | por |
dc.subject | Human serum albumin (HSA) | por |
dc.subject | ADMET | por |
dc.subject | PK prediction | por |
dc.title | A biophysical insight of Camptothecin biodistribution: towards a molecular understanding of its pharmacokinetic issues | por |
dc.type | article | por |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.mdpi.com/1999-4923/13/6/869 | por |
oaire.citationStartPage | 1 | por |
oaire.citationEndPage | 24 | por |
oaire.citationIssue | 6 | por |
oaire.citationVolume | 13 | por |
dc.date.updated | 2021-06-24T14:12:07Z | - |
dc.identifier.eissn | 1999-4923 | - |
dc.identifier.doi | 10.3390/pharmaceutics13060869 | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Pharmaceutics | por |
oaire.version | VoR | por |
Aparece nas coleções: |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
pharmaceutics-13-00869-v2.pdf | 2,63 MB | Adobe PDF | Ver/Abrir |
Este trabalho está licenciado sob uma Licença Creative Commons